Cell Biochemistry and Biophysics

, Volume 70, Issue 3, pp 1617–1623 | Cite as

Evaluation of the Association Between CD143 Gene Polymorphism and Psoriasis

Original Paper


Increased CD143 activity has been detected in various skin tissues, and this increase is partially caused by the intronic ID polymorphism. The genetic contribution of CD143 ID polymorphism to the progression of psoriasis, the commonest skin disease, has been extensively investigated, but reported with inconsistent results. The aim of this work was to gain new insights to shed light on the association between CD143 ID polymorphism and psoriasis risk. We systematically identified the studies examining the association of CD143 ID polymorphism with psoriasis risk. A meta-analysis combining data from all eligible studies was carried out. To evaluate the genetic association, we calculated odds ratio (OR) and its 95 % confidence intervals (CIs) for both genotypic models and allelic model. The final pooling dataset comprised ten studies. Meta-analysis of total samples did not suggest a notable association with psoriasis risk. However, subgroup analysis by ethnicity revealed a statistically significant association in East Asian samples (DD + ID vs. II: OR 0.86, 95 % CI 0.75–0.99, Pheterogeneity = 0.970; DD vs. ID: OR 0.85, 95 % CI 0.73–0.99, Pheterogeneity = 0.868; D vs. I: OR 0.86, 95 % CI 0.76–0.97, Pheterogeneity = 0.994). This meta-analysis demonstrated that the presence of CD143 ID polymorphism may modify the risk of psoriasis in individuals with East Asian ancestry.


CD143 Insertion/deletion polymorphism Psoriasis risk 


  1. 1.
    Parisi, R., et al. (2013). Global epidemiology of psoriasis: A systematic review of incidence and prevalence. Journal of Investigative Dermatology, 133(2), 377–385.PubMedCrossRefGoogle Scholar
  2. 2.
    Cai, Y., Fleming, C., & Yan, J. (2012). New insights of T cells in the pathogenesis of psoriasis. Cellular & Molecular Immunology, 9(4), 302–309.CrossRefGoogle Scholar
  3. 3.
    Schon, M. P., & Boehncke, W. H. (2005). Psoriasis. New England Journal of Medicine, 352(18), 1899–1912.PubMedCrossRefGoogle Scholar
  4. 4.
    Huerta, C., Rivero, E., & Rodriguez, L. A. (2007). Incidence and risk factors for psoriasis in the general population. Archives of Dermatology, 143(12), 1559–1565.PubMedCrossRefGoogle Scholar
  5. 5.
    Nestle, F. O., Kaplan, D. H., & Barker, J. (2009). Psoriasis. New England Journal of Medicine, 361(5), 496–509.PubMedCrossRefGoogle Scholar
  6. 6.
    Valdimarsson, H., et al. (2009). Psoriasis–as an autoimmune disease caused by molecular mimicry. Trends in Immunology, 30(10), 494–501.PubMedCrossRefGoogle Scholar
  7. 7.
    Reich, K., et al. (2002). Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. Journal of Investigative Dermatology, 118(1), 155–163.PubMedCrossRefGoogle Scholar
  8. 8.
    Hensen, P., et al. (2003). Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. British Journal of Dermatology, 149(2), 381–385.PubMedCrossRefGoogle Scholar
  9. 9.
    Koks, S., et al. (2005). Possible relations between the polymorphisms of the cytokines IL-19, IL-20 and IL-24 and plaque-type psoriasis. Genes and Immunity, 6(5), 407–415.PubMedCrossRefGoogle Scholar
  10. 10.
    Campalani, E., et al. (2006). Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. British Journal of Dermatology, 154(2), 345–352.PubMedCrossRefGoogle Scholar
  11. 11.
    Plant, D., et al. (2006). The CX3CL1-CX3CR1 system and psoriasis. Experimental Dermatology, 15(11), 900–903.PubMedCrossRefGoogle Scholar
  12. 12.
    Rice, G. I., et al. (2006). Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension, 48(5), 914–920.PubMedCrossRefGoogle Scholar
  13. 13.
    Petrov, V., Fagard, R., & Lijnen, P. (2000). Effect of protease inhibitors on angiotensin-converting enzyme activity in human T-lymphocytes. American Journal of Hypertension, 13(5 Pt 1), 535–539.PubMedCrossRefGoogle Scholar
  14. 14.
    Zagato, L., et al. (2005). Direct assessment of angiotensin-converting enzyme activity on the surface of human skin fibroblasts in culture. Analytical Biochemistry, 338(2), 344–346.PubMedCrossRefGoogle Scholar
  15. 15.
    Huskic, J., & Alendar, F. (2007). Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosnian Journal of Basic Medical Sciences, 7(2), 103–106.PubMedGoogle Scholar
  16. 16.
    Huskic, J., et al. (2008). Serum and tissue angiotensin converting enzyme in patients with psoriasis. Collegium Antropologicum, 32(4), 1215–1219.PubMedGoogle Scholar
  17. 17.
    Rigat, B., et al. (1990). An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. Journal of Clinical Investigation, 86(4), 1343–1346.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Ozkur, M., et al. (2004). Association of insertion/deletion polymorphism of the angiotensin-converting enzyme gene with psoriasis. British Journal of Dermatology, 151(4), 792–795.PubMedCrossRefGoogle Scholar
  19. 19.
    Chang, Y. C., et al. (2007). Association between the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene and risk for psoriasis in a Chinese population in Taiwan. British Journal of Dermatology, 156(4), 642–645.PubMedCrossRefGoogle Scholar
  20. 20.
    Liu XH, Z.S., Zhao ZQ, Zhao D, Song LY, Yang H (2007) Study on the relationship between insertion/deletion polymorphism of angiotensin-converting enzyme gene with psoriasis. Chinese Journal of Dermatology Venere. 21, 199–200.Google Scholar
  21. 21.
    Higgins, J. P., et al. (2003). Measuring inconsistency in meta-analyses. BMJ, 327(7414), 557–560.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Mantel, N., & Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute, 22(4), 719–748.PubMedGoogle Scholar
  23. 23.
    DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. Controlled Clinical Trials, 7(3), 177–188.PubMedCrossRefGoogle Scholar
  24. 24.
    A, T., Assessing the influence of a single study in the meta-analysis estimate 8. Stata Tech Bull, 1999: p. 15–17.Google Scholar
  25. 25.
    Egger, M., et al. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629–634.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Weger, W., et al. (2007). The angiotensin-converting enzyme insertion/deletion and the endothelin -134 3A/4A gene polymorphisms in patients with chronic plaque psoriasis. Experimental Dermatology, 16(12), 993–998.PubMedCrossRefGoogle Scholar
  27. 27.
    Nagui, N. A., Hay, M. R. A., & Rashed, L. (2012). Association between the angiotensin-converting enzyme gene insertion/deletion polymorphism and the risk for psoriasis. Journal of the Egyptian Women’s Dermatologic Society, 9, 14–17.CrossRefGoogle Scholar
  28. 28.
    Al-Awadhi, A. M., et al. (2007). Angiotensin-converting enzyme gene polymorphism in patients with psoriatic arthritis. Rheumatology International, 27(12), 1119–1123.PubMedCrossRefGoogle Scholar
  29. 29.
    Veletza, S., et al. (2008). Assessment of insertion/deletion polymorphism of the angiotensin converting enzyme gene in psoriasis. Journal of Dermatological Science, 49(1), 85–87.PubMedCrossRefGoogle Scholar
  30. 30.
    Coto-Segura, P., et al. (2009). Lack of association between angiotensin I-converting enzyme insertion/deletion polymorphism and psoriasis or psoriatic arthritis in Spain. International Journal of Dermatology, 48(12), 1320–1323.PubMedCrossRefGoogle Scholar
  31. 31.
    Yang, K., et al. (2014). Angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to psoriasis in a Chinese population. Journal of Renin-Angiotensin-Aldosterone System, 15(1), 39–43.CrossRefGoogle Scholar
  32. 32.
    Vasku, V., Vašků, A., Holla, L., Kaokova, K., Znojil, V., Semradova, V., et al. (1999). Interaction of five gene polymorphisms at psoriasis. Journal of Investigative Dermatology, 113, 494.Google Scholar
  33. 33.
    Song, G.G., et al., The angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to rheumatoid arthritis, vitiligo and psoriasis: A meta-analysis. Journal of Renin-Angiotensin-Aldosterone System, 2013.Google Scholar
  34. 34.
    Murphey, L. J., et al. (2000). Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation, 102(8), 829–832.PubMedCrossRefGoogle Scholar
  35. 35.
    Ryder, K. W., et al. (1985). Serum angiotensin converting enzyme activity in patients with psoriasis. Clinica Chimica Acta, 153(2), 143–146.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Chinese PLA General HospitalBeijingChina
  2. 2.Department of Dermatology306 Hospital of PLABeijingChina
  3. 3.Department of Neuro-Oncology SurgeryThe General Hospital of Chinese People’s Armed Police ForcesBeijingChina
  4. 4.Department of Intensive Care MedicineJinan Military General HospitalJinanChina
  5. 5.Department of HealthManagement Security Department of General Staff, PLABeijingChina
  6. 6.Department of Stomatology306 Hospital of PLABeijingChina
  7. 7.Department of DermatologyChinese PLA General HospitalBeijingChina

Personalised recommendations